Abstract:The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein–protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure–activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified 19a as the most potent inhibitor in this series, with an IC50 of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of 19a. Compound 19a dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01116?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01116</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01116/suppl_file/jm0c01116_si_001.csv">CSV</a>)Characterization of the representative intermediates, characterization of the target compounds, Keap1 Kelch domain expression and purification, FP competition assay, binding mode of compound 15 with Keap1, determination of thermodynamic data based on tracer displacement assay, ITC assay, BLI assay, ARE-luciferase activity assay, cell viability assay, RNA extraction and qRT-PCR analysis, Western blot analysis, IL-1β, IL-6, and TNF-α production, evaluation of GSH/GSSG ratio, detection of ROS level, animal experiments, statistical analysis and 1H NMR, 13C NMR, HRMS and HPLC spectra for representative target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01116/suppl_file/jm0c01116_si_002.pdf">PDF</a>)This article has not yet been cited by other publications.

Novel Protein–protein Interaction Inhibitor of Nrf2–Keap1 Discovered by Structure-Based Virtual Screening

Discovery of Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis.

Rapid Identification of Keap1-Nrf2 Small-Molecule Inhibitors Through Structure-Based Virtual Screening and Hit-Based Substructure Search

Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor

Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitor with Natural Proline Structure As a Cytoprotective Agent Against Acetaminophen-Induced Hepatotoxicity

Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors

Small Molecules Inhibiting Keap1-Nrf2 Protein-Protein Interactions: A Novel Approach to Activate Nrf2 Function

Discovery of a Head-to-tail Cyclic Peptide As the Keap1-Nrf2 Protein-Protein Interaction Inhibitor with High Cell Potency

Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N'-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction

Discovery of 2-Oxy-2-phenylacetic Acid Substituted Naphthalene Sulfonamide Derivatives As Potent KEAP1-NRF2 Protein-Protein Interaction Inhibitors for Inflammatory Conditions.

Discovery of Keap1−Nrf2 small−molecule inhibitors from phytochemicals based on molecular docking

Modified Peptide Inhibitors of the Keap1–Nrf2 Protein–Protein Interaction Incorporating Unnatural Amino Acids

Design, Synthesis, and Structure–Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein–Protein Interaction Inhibitors

Updated Research and Applications of Small Molecule Inhibitors of Keap1-Nrf2 Protein-Protein Interaction: a Review.

Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.

Structure-Guided Conformational Restriction Leading to High-Affinity, Selective, and Cell-Active Tetrahydroisoquinoline-Based Noncovalent Keap1-Nrf2 Inhibitors

Discovery of Propionic Acid Derivatives with a 5-THIQ Core as Potent and Orally Bioavailable Keap1-Nrf2 Protein-Protein Interaction Inhibitors for Acute Kidney Injury

Recent progress on small-molecule inhibitors of Nrf2-Keap1 protein-protein interaction

Discovery and Development of Kelch-Like Ech-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (keap1:Nrf2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions

Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors

KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential